Zymeworks Inc. (NASDAQ: ZYME) will present clinical and preclinical data on its antibody-drug conjugate programs at the American Association for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE